全文获取类型
收费全文 | 2052177篇 |
免费 | 159254篇 |
国内免费 | 29380篇 |
专业分类
耳鼻咽喉 | 24473篇 |
儿科学 | 60301篇 |
妇产科学 | 50140篇 |
基础医学 | 279723篇 |
口腔科学 | 54561篇 |
临床医学 | 202909篇 |
内科学 | 380949篇 |
皮肤病学 | 42509篇 |
神经病学 | 148147篇 |
特种医学 | 77151篇 |
外国民族医学 | 466篇 |
外科学 | 288309篇 |
综合类 | 108057篇 |
现状与发展 | 90篇 |
一般理论 | 560篇 |
预防医学 | 150928篇 |
眼科学 | 50423篇 |
药学 | 163004篇 |
439篇 | |
中国医学 | 28691篇 |
肿瘤学 | 128981篇 |
出版年
2022年 | 19413篇 |
2021年 | 30693篇 |
2020年 | 22223篇 |
2019年 | 24907篇 |
2018年 | 31725篇 |
2017年 | 26614篇 |
2016年 | 27065篇 |
2015年 | 35363篇 |
2014年 | 46620篇 |
2013年 | 56464篇 |
2012年 | 80171篇 |
2011年 | 86337篇 |
2010年 | 53730篇 |
2009年 | 47703篇 |
2008年 | 72101篇 |
2007年 | 75149篇 |
2006年 | 74628篇 |
2005年 | 71128篇 |
2004年 | 62901篇 |
2003年 | 59855篇 |
2002年 | 55937篇 |
2001年 | 99323篇 |
2000年 | 100913篇 |
1999年 | 84520篇 |
1998年 | 24753篇 |
1997年 | 22156篇 |
1996年 | 21219篇 |
1995年 | 20336篇 |
1994年 | 18319篇 |
1993年 | 16010篇 |
1992年 | 59441篇 |
1991年 | 57074篇 |
1990年 | 54512篇 |
1989年 | 52056篇 |
1988年 | 47212篇 |
1987年 | 45928篇 |
1986年 | 42982篇 |
1985年 | 40536篇 |
1984年 | 29628篇 |
1983年 | 25106篇 |
1982年 | 13995篇 |
1979年 | 25631篇 |
1978年 | 17631篇 |
1977年 | 14948篇 |
1976年 | 13902篇 |
1975年 | 14587篇 |
1974年 | 17661篇 |
1973年 | 16974篇 |
1972年 | 15702篇 |
1971年 | 14472篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
91.
M. R. D. Maslin S. K. Lloyd S. Rutherford S. Freeman A. King D. R. Moore K. J. Munro 《Journal of the Association for Research in Otolaryngology》2015,16(5):631-640
Individuals with sudden unilateral deafness offer a unique opportunity to study plasticity of the binaural auditory system in adult humans. Stimulation of the intact ear results in increased activity in the auditory cortex. However, there are no reports of changes at sub-cortical levels in humans. Therefore, the aim of the present study was to investigate changes in sub-cortical activity immediately before and after the onset of surgically induced unilateral deafness in adult humans. Click-evoked auditory brainstem responses (ABRs) to stimulation of the healthy ear were recorded from ten adults during the course of translabyrinthine surgery for the removal of a unilateral acoustic neuroma. This surgical technique always results in abrupt deafferentation of the affected ear. The results revealed a rapid (within minutes) reduction in latency of wave V (mean pre = 6.55 ms; mean post = 6.15 ms; p < 0.001). A latency reduction was also observed for wave III (mean pre = 4.40 ms; mean post = 4.13 ms; p < 0.001). These reductions in response latency are consistent with functional changes including disinhibition or/and more rapid intra-cellular signalling affecting binaurally sensitive neurons in the central auditory system. The results are highly relevant for improved understanding of putative physiological mechanisms underlying perceptual disorders such as tinnitus and hyperacusis. 相似文献
92.
93.
目的研究葛根素联合复方樟柳碱注射液对眼底病患者的治疗效果及对血液流变学指标的影响。方法选择2013年4月至2014年4月在绵阳市第三人民医院眼科进行眼底病治疗的患者100例,并按入院顺序抽签随机分为观察组和对照组,各50例。对照组进行葛根素常规治疗(葛根素注射液0.4 g加入生理盐水250 m L中静脉滴注,每日1次,1个疗程14 d,1个疗程后停药3 d,再进行下一疗程),观察组在此基础上联合复方樟柳碱注射液进行治疗(采用复方樟柳碱2 m L在患者颞浅动脉旁行皮下注射,每日1次,1个疗程14 d,完成1个疗程后停药3 d,再换肾俞穴进行注射,1个疗程后停药3 d,再进行第一个疗程的用药)。3个疗程后,比较两组患者治疗前后血液流变学的变化、术后复发率和不良反应情况及患者的治疗效果。结果治疗后,观察组全血黏度为(4.82±0.41)m Pa·s明显低于对照组的(5.56±0.39)m Pa·s,红细胞聚集指数(3.80±0.41)明显低于对照组(4.77±0.55),纤维蛋白原(4.20±0.24)g/L明显低于对照组(5.25±0.43)g/L,差异均有统计学意义(t=9.247,9.998,15.077,P<0.01);观察组患者治疗后复发率为2.0%(1/50),不良反应的总发生率为4.0%(2/50),分别低于对照组14.0%(7/50)和18.0%(9/50)(P<0.01);观察组患者的总有效率为98.0%(49/50),显著高于对照组的82.0%(41/50)(P<0.05)。结论葛根素和复方樟柳碱注射液联合治疗眼底病患者,可改善患者血液流变学,并提高临床治疗效果。 相似文献
94.
95.
Benyam Kinde Harrison W. Gabel Caitlin S. Gilbert Eric C. Griffith Michael E. Greenberg 《Proceedings of the National Academy of Sciences of the United States of America》2015,112(22):6800-6806
DNA methylation at CpG dinucleotides is an important epigenetic regulator common to virtually all mammalian cell types, but recent evidence indicates that during early postnatal development neuronal genomes also accumulate uniquely high levels of two alternative forms of methylation, non-CpG methylation and hydroxymethylation. Here we discuss the distinct landscape of DNA methylation in neurons, how it is established, and how it might affect the binding and function of protein readers of DNA methylation. We review studies of one critical reader of DNA methylation in the brain, the Rett syndrome protein methyl CpG-binding protein 2 (MeCP2), and discuss how differential binding affinity of MeCP2 for non-CpG and hydroxymethylation may affect the function of this methyl-binding protein in the nervous system. 相似文献
96.
97.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
98.
99.
Provocation of Atrial Fibrillation Triggers During Ablation: Does the Use of General Anesthesia Affect Inducibility? 下载免费PDF全文
100.
Changhyun Kim B.S. Brittany G. Craiglow M.D. Kalman L. Watsky M.D. Richard J. Antaya M.D. 《Pediatric dermatology》2015,32(4):e161-e162
A 17‐year‐old boy presented with recurring severe dermatitis of the face of 5‐months duration that resembled impetigo. He had been treated with several courses of antibiotics without improvement. Biopsy showed changes consistent with allergic contact dermatitis and patch testing later revealed sensitization to benzoyl peroxide, which the patient had been using for the treatment of acne vulgaris. 相似文献